20/20 Bio Labs

Coming – October 5

Rethinking Early Cancer Detection

Date and Time

October 5

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

What if detecting cancer earlier was less about taking one expensive test and more about watching for changes in your body over time? That is the idea behind 20/20 BioLabs (NASDAQ: AIDX), a commercial-stage diagnostics company making early detection of cancer and chronic disease more affordable, accessible, and actionable.

Its flagship OneTest™ for Cancer takes a different approach from many other multi-cancer early detection tests. Rather than relying primarily on tumor DNA circulating in the blood, OneTest measures established protein tumor markers and uses machine learning to identify patterns associated with multiple cancers.

Now, a major change in Medicare could dramatically expand that opportunity beyond the company’s current customer base of firefighters, military personnel, and other organizations. Legislation signed into law in February 2026 creates a pathway for Medicare to cover qualifying FDA-authorized multi-cancer early detection tests, potentially opening access to tens of millions of beneficiaries.

The company is also working to turn cancer screening from an annual snapshot into an ongoing early-warning system. Affordability is critical to making that model work. OneTest starts at under $200, versus roughly $1,000 for some competing DNA-based MCED tests, and uses a blood collection device that makes at-home testing practical.

Register for this executive briefing with 20/20 BioLabs President & CEO, Jonathan Cohen, to hear why the company reported record quarterly cancer-testing revenue in Q2 2026 and has plans to leverage their platform to create a broader longevity test.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.